Early use of risdiplam in newborns with SMA shows improvements in motor development

Spinal muscular atrophy (SMA) is a rare genetic condition that causes progressive muscle weakness, which, when untreated, prevents infants with the most severe form from gaining motor development – never gaining the ability to sit – and typically leads to death before 2 years of age.